- Home
- ANVS vs ALGS Comparison
ANVS vs ALGS Comparison
Compare ANVS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | ALGS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 43.0M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANVS | ALGS |
|---|---|---|
| Price | $2.57 | $7.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.50 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 314.1K | 33.8K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.92 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $3.76 |
| 52 Week High | $5.50 | $13.69 |
Technical Indicators
Market Signals| Indicator | ANVS | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 47.30 |
| Support Level | $2.27 | $6.92 |
| Resistance Level | $2.63 | $7.50 |
| Average True Range (ATR) | 0.20 | 0.55 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 33.85 | 65.13 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.